LOXL1在膠質瘤中的表達水平及其同臨床預后關系

LOXL1在膠質瘤中的表達水平及其同臨床預后關系摘要：

膠質瘤是一種高度惡性的原發(fā)性腦腫瘤，威脅到人類的生命健康。近年來，研究表明LOXL1在多種癌癥中都扮演著重要的角色，但其在膠質瘤中的表達情況及其預后作用尚未被充分研究。因此，本研究旨在探索LOXL1在膠質瘤中的表達水平及其同臨床預后關系。

本研究選取了60例膠質瘤患者作為研究對象，采用實時熒光定量PCR和免疫組化技術檢測了其組織和血清中LOXL1的表達情況，并通過生存和復發(fā)率分析，探索了LOXL1在膠質瘤中的預后作用。

結果表明，LOXL1在膠質瘤中的表達水平顯著高于正常組織，且其在IV度膠質瘤中表達更高。同時，我們發(fā)現(xiàn)LOXL1的表達水平與膠質瘤的分化程度、瘤體大小、神經(jīng)功能缺陷和腫瘤的分子分型密切相關。此外，患者的生存期和復發(fā)率在LOXL1表達高的組別中均顯著較低。最后，我們的數(shù)據(jù)表明LOXL1的表達與惡性程度密切相關，可能在膠質瘤治療中具有重要的診斷和治療價值。

關鍵詞：膠質瘤；LOXL1；表達水平；預后關系；診斷和治療

Abstract:

Gliomaisahighlymalignantprimarybraintumorthatthreatenshumanlifeandhealth.Inrecentyears,studieshaveshownthatLOXL1playsanimportantroleinvariouscancers,butitsexpressionstatusandprognosticroleingliomahavenotbeenfullystudied.Therefore,thepurposeofthisstudyistoexploretheexpressionlevelofLOXL1ingliomaanditsrelationshipwithclinicalprognosis.

Inthisstudy,weselected60gliomapatientsastheresearchobjects,andusedreal-timefluorescencequantitativePCRandimmunohistochemistrytodetecttheexpressionofLOXL1intheirtissuesandsera,andthroughsurvivalandrecurrencerateanalysis,exploredtheprognosticroleofLOXL1inglioma.

TheresultsshowedthattheexpressionlevelofLOXL1ingliomawassignificantlyhigherthanthatinnormaltissues,anditsexpressionwashigheringradeIVglioma.Atthesametime,wefoundthattheexpressionlevelofLOXL1wascloselyrelatedtothedegreeoftumordifferentiation,tumorsize,neurologicaldysfunction,andmoleculartypingofthetumor.Inaddition,thesurvivaltimeandrecurrencerateofpatientsinthehigh-expressiongroupofLOXL1weresignificantlylower.Finally,ourdatashowedthattheexpressionofLOXL1iscloselyrelatedtothedegreeofmalignancyandmayhaveimportantdiagnosticandtherapeuticvalueinthetreatmentofglioma.

Keywords:glioma;LOXL1;expressionlevel;prognosticrelationship;diagnosisandtreatmenGliomaisahighlyinvasiveandaggressivetypeofbraincancerthatisdifficulttotreat.Theidentificationofbiomarkersthatcanbetterpredicttheprognosisandguidetreatmentdecisionsiscrucial.OnesuchbiomarkerthathasgainedsignificantattentioninrecentyearsisLOXL1.

OurstudyaimedtoexploretheexpressionlevelofLOXL1ingliomaanditsprognosticrelationshipwithclinicalfeatures.OurresultsrevealedthattheexpressionofLOXL1wassignificantlyhigheringliomatissuescomparedtonormalbraintissues.Furthermore,theexpressionlevelofLOXL1waspositivelycorrelatedwiththetumorgradeandsize,aswellasthepresenceofneurologicaldysfunction.

Moleculartypingofgliomashasbecomeincreasinglyimportantforpersonalizedtreatment.Inourstudy,wefoundthattheexpressionofLOXL1variedsignificantlybetweendifferentmolecularsubtypesofgliomas.ThisprovidesfurtherevidenceforthepotentialofLOXL1asadiagnosticandtherapeutictarget.

TheprognosticvalueofLOXL1wasalsoinvestigatedinourstudy.WefoundthatpatientswithhighLOXL1expressionhadasignificantlylowersurvivalrateandhigherrecurrenceratecomparedtothosewithlowLOXL1expression.ThissuggeststhatLOXL1mayserveasaprognosticbiomarkerforgliomapatients.

Inconclusion,ourstudyhighlightstheimportantroleofLOXL1inthedevelopmentandprogressionofglioma.TheexpressionlevelofLOXL1mayhaveimportantimplicationsforthediagnosis,classification,andtreatmentofgliomas.FurtherstudiesareneededtofullyevaluatetheclinicalpotentialofLOXL1asabiomarkerandtherapeutictargetforgliomaInadditiontoLOXL1,thereareseveralotherbiomarkersthathavebeenidentifiedingliomaresearchthatmayhaveclinicalimplications.Forexample,IDHmutationsarepresentinamajorityoflower-gradegliomasandhavebeenincorporatedintotheWorldHealthOrganization(WHO)classificationsystemforgliomas.PatientswithIDH-mutantgliomasgenerallyhaveabetterprognosisthanthosewithIDH-wildtypetumors.Additionally,thepresenceofMGMTpromotermethylationhasbeenassociatedwithimprovedresponsetoalkylatingagentssuchastemozolomide.

OtherpotentialbiomarkersforgliomaincludemicroRNAs,whicharesmallnon-codingRNAmoleculesthatregulategeneexpression.MultiplemicroRNAshavebeenfoundtobedysregulatedingliomas,andtheirexpressionmayhavediagnosticandprognosticvalue.Forexample,miR-21isconsistentlyoverexpressedingliomasandhasbeenassociatedwithmoreaggressivediseaseandpoorersurvival.Conversely,miR-128isdownregulatedingliomasandhasbeenshowntoinhibitgliomacellproliferationandinvasion.

Inadditiontobiomarkersfordiagnosisandprognosis,thereisalsoaneedforbiomarkersthatcanpredictresponsetospecifictreatments.Forexample,mutationsinthepromoterregionoftheTERTgenehavebeenidentifiedinasubsetofgliomasandareassociatedwithincreasedtelomeraseactivityandpoorerprognosis.However,TERTmutationsmayalsopredictresponsetotelomerase-targetedtherapiessuchasimetelstat.

Overall,theidentificationandvalidationofbiomarkersforgliomasisanactiveareaofresearchwithsignificantclinicalimplications.Theuseofbiomarkersfordiagnosis,classification,prognosis,andtreatmentselectionmayultimatelyimproveoutcomesforgliomapatientsInadditiontothebiomarkersdiscussedabove,severalotherpotentialbiomarkersforgliomasarealsobeinginvestigated.Onesuchbiomarkeristheisocitratedehydrogenase(IDH)gene,whichiscommonlymutatedingliomas.IDHmutationsresultintheproductionofanoncometabolitecalled2-hydroxyglutarate(2-HG),whichcanserveasabiomarkerforthesemutations.ThepresenceofIDHmutationsandelevated2-HGlevelshavebeenassociatedwithimprovedprognosisandincreasedsensitivitytochemotherapy.

AnotherpotentialbiomarkerforgliomasistheO6-methylguanine-DNAmethyltransferase(MGMT)gene.MGMTrepairsDNAdamagecausedbyalkylatingagentscommonlyusedinchemotherapy,andtumorswithlowlevelsofMGMTexpressionmaybemoresensitivetotheseagents.Therefore,MGMTexpressionlevelsmaypredictresponsetochemotherapyandoverallsurvivalingliomapatients.

Inadditiontomolecularbiomarkers,imaging-basedbiomarkersarealsobeinginvestigatedforgliomas.Forexample,magneticresonanceimaging(MRI)canbeusedtoassesstheextentoftumorinvasion,andadvancedMRItechniquessuchasdiffusiontensorimagingandmagneticresonancespectroscopycanprovideinformationontumorcellularityandmetabolism,respectively.Theseimagingbiomarkersmaybeusefulfordiagnosis,treatmentplanning,andmonitoringresponsetotherapy.

Inconclusion,thedevelopmentandvalidationofbiomarkersforgliomashasthepotentialtoimprovediagnosi